Vir Amends Collaboration Agreement with GSK

  Vir to continue advancing next-generation COVID-19 solutions independently or with other partners –

– The Companies will continue working together to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to advance new therapies for influenza and other respiratory diseases –

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the research collaboration agreement established with GSK in 2020 has been amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners. Together, the Companies will continue working to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to develop new therapies for influenza and other respiratory diseases.

https://finance.yahoo.com/news/vir-biotechnology-announces-amended-collaboration-214500824.html